Brought to you by 
Cell Genesys, Mitotix in gene therapy collaboration
21 Mar 2002
Executive Summary
Mitotix (cell proliferation disorders) agreed to give Cell Genesys (gene therapies) worldwide, exclusive rights to three cell cycle genes for development of gene therapy products for cardiovascular disease and other indications.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cell Genesys, Mitotix in gene therapy collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice